- $182.21bn
- $227.49bn
- $36.75bn
Kennedy's health officials explored US ban of some widely used antidepressants, sources say
Viridian eye disease drug benefits chronic patients in late-stage trial; shares soar (updated)
Viridian eye disease drug benefits chronic patients in late-stage trial
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Amgen to invest additional $300 million to boost US manufacturing footprint
Brief: Amgen Announces Additional $300 Million U.S. Manufacturing Investment, Totaling Nearly $2 Billion Over The Last Year
U.S. RESEARCH ROUNDUP- Alphabet, Colgate-Palmolive, Welltower
Live Markets: S&P, Nasdaq close at records as Amgen weighs on Dow
Amgen falls on concerns about tax litigation with the IRS
Amgen sales rise 4% in first quarter, broadens weight-loss drug development (updated)
Amgen Q1 revenue rises
Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
PREVIEW: Amgen shares higher with results on deck
US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals
Brief: Paradigm Health Collaborates With FDA To Transform Regulatory Review Of Clinical Trial Data
U.S. STOCKS ON THE MOVE-AxoGen, energy companies, Corning
U.S. STOCKS ON THE MOVE-Enterprise Products, Sherwin-Williams, Veradermics
U.S. STOCKS ON THE MOVE- Kimberly-Clark, JetBlue, Amgen